Ferroptosis-centered Drug Response Information
General Information of the Drug (ID: ferrodrug0161)
| Name |
D-Mannose
|
||||
|---|---|---|---|---|---|
| Synonyms |
D-Man; D-Mannopyranose; D-Mannopyranoside; D-Mannose; Man; Mannopyranose; Mannopyranoside; Mannose; Carubinose; Seminose; 530-26-7; D-(+)-Mannose; (+)-Mannose; CHEBI:4208; (3S,4S,5S,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol; D-Mannose 1000 microg/mL in Methanol; AI3-18442; MFCD00064122; (+-)-Mannose; SMR000857125; 2h-pyran-2,3,4,5-tetraol; manno-hexose; NSC 26247; D-Mannose,(S); alpha,beta-D-mannopyranose; bmse000018; bmse000874; bmse000882; Epitope ID:152206; SCHEMBL38300; MLS001332527; MLS001332528; CHEMBL469448; GTPL4650; DTXCID3020463; CHEBI:16024; CHEBI:37684; DTXSID501337491; HMS2236J04; BDBM50448403; s5763; AKOS025212856; D-(+)-Mannose, synthetic, >=99%; DS-3390; D-(+)-Mannose, from wood, >=99%; D-(+)-Mannose, p.a., 99.0%; NCGC00166108-01; 46032-76-2; AC-11148; D-(+)-Mannose, for microbiology, >=99%; CS-0238447; M0045; EN300-19556; (3S,4S,5S,6R)-6-(hydroxymethyl)tetrahydro-; C00159; A829355; Q335208; D50D2EC9-C1E4-4213-AFF7-F9C678AC92C5; Z104474216; (3S,4S,5R,6R)-6-methyloltetrahydropyran-2,3,4,5-tetrol; D-(+)-Mannose, powder, BioReagent, suitable for cell culture; Mannose, United States Pharmacopeia (USP) Reference Standard; (3S,4S,5R,6R)-6-(hydroxymethyl)tetrahydropyran-2,3,4,5-tetrol; (3S,4S,5S,6R)-6-(hydroxymethyl)tetrahydropyran-2,3,4,5-tetrol; D-(+)-Mannose, BioUltra, >=99.5% (sum of enantiomers, HPLC); (3S,4S,5S,6R)-6-(hydroxymethyl)tetrahydro-2H-pyran-2,3,4,5-tetraol; D-(+)-Mannose, for microbiology, >=99.0% (sum of enantiomers, HPLC)
Click to Show/Hide
|
||||
| Status |
Investigative
|
||||
| Drug Type |
Small molecular drug
|
||||
| Structure |
 |
||||
| Formula |
C6H12O6
|
||||
| IUPAC Name |
(3S,4S,5S,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol
|
||||
| Canonical SMILES |
C(C1C(C(C(C(O1)O)O)O)O)O
|
||||
| InChI |
InChI=1S/C6H12O6/c7-1-2-3(8)4(9)5(10)6(11)12-2/h2-11H,1H2/t2-,3-,4+,5+,6?/m1/s1
|
||||
| InChIKey |
WQZGKKKJIJFFOK-QTVWNMPRSA-N
|
||||
| PubChem CID | |||||
| TTD Drug ID | |||||
Full List of Ferroptosis Target Related to This Drug
Cystine/glutamate transporter (SLC7A11)
| In total 1 item(s) under this Target | |||||
| Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | ||||
| Target for Ferroptosis | Suppressor | ||||
| Responsed Disease | Degenerative arthritis | ICD-11: FA05 | |||
| Responsed Regulator | Endothelial PAS domain-containing protein 1 (EPAS1) | Driver | |||
| Pathway Response | Fatty acid metabolism | hsa01212 | |||
| Ferroptosis | hsa04216 | ||||
| Cell Process | Cell ferroptosis | ||||
| In Vitro Model | hCDs (Chondrocytes) | ||||
| In Vivo Model |
C57BL/6 J mice (8 weeks old, female) were purchased from Dossy Experimental Animal Limited Company (Chengdu, China). For surgery, mice were anaesthetized with pentobarbital sodium (100 mg/kg, injected intraperitoneally) and subjected to unilateral ACLT procedures. 28 The sham group received a skin incision and suturing without patellar dislocation or ligament transection. For virus injection, mice were intraarticularly injected with 1 x 109 pfu (8 ul) of mock or AdEpas1 virus after one week of surgery. For Fer1 (MCE, Monmouth Junction, HY100579) injection, mice were intraarticularly injected with 1 mg/kg Fer1 or with vehicle two weeks after surgery, the injection was repeated once a week.
Click to Show/Hide
|
||||
| Response regulation | D-mannose alleviates osteoarthritis (OA) progression by suppressing HIF-2a-mediated chondrocyte sensitivity to ferroptosis. Overexpression of HIF-2a in chondrocytes by Ad- Epas1 intra-articular injection abolished the chondroprotective effect of D-mannose during OA progression and eliminated the role of D-mannose as a ferroptosis suppressor. Also, the RNA and protein levels of the two key ferroptosis suppressors, Gpx4 and Slc7a11, were increased in Dmannosetreated chondrocytes. | ||||